110234-43-0

Basic information

• Product Name: 3-Isoxazolamine,5-(trifluoromethyl)-(9CI)
• Synonyms: 3-Isoxazolamine,5-(trifluoromethyl)-(9CI);5-(trifluoromethyl)-3-Isoxazolamine;5-TrifluoroMethyl-isoxazol-3-ylaMine;3-Amino-5-(trifluoromethyl)isoxazole;5-Trifluoromethyl-3-aminoisoxazole;5-(trifluoromethyl)isoxazol-3-amin
• CAS NO: 110234-43-0
• Molecular Formula: C4H3F3N2O
• Molecular Weight: 152.075
• EINECS: 604-604-1
• Product Categories: OXAZOLE
• Mol File: 110234-43-0.mol
• Article Data: 2

Chemical Properties

• Melting Point: 57-58℃
• Boiling Point: 66-67℃ (0.8 Torr)
• Appearance: /
• Density: 1.502±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C(protect from light)
• PKA: 1.05±0.10(Predicted)
• CAS DataBase Reference: 3-Isoxazolamine,5-(trifluoromethyl)-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Isoxazolamine,5-(trifluoromethyl)-(9CI)(110234-43-0)
• EPA Substance Registry System: 3-Isoxazolamine,5-(trifluoromethyl)-(9CI)(110234-43-0)

Safety Data

• Hazardous Substances Data: 110234-43-0(Hazardous Substances Data)

Usage

General Description

3-Isoxazolamine, 5-(trifluoromethyl)-(9CI) is a chemical compound with the molecular formula C5H4F3NO. 3-Isoxazolamine,5-(trifluoromethyl)-(9CI) is a derivative of isoxazole and contains a trifluoromethyl group. It is used in the pharmaceutical and agrochemical industries as a building block for the synthesis of various compounds. The trifluoromethyl group is known for its ability to enhance the biological activity and metabolic stability of molecules, making it of interest in drug discovery and development. Additionally, this compound may also have applications in materials science and other fields due to its unique properties and reactivity. Further research and experimentation on this chemical may reveal its full potential in different applications.

Upstream product

• 110235-11-5 N-[5-(trifluoromethyl)isoxazol-3-yl]benzamide 
• 110234-68-9 3-cyano-1,1,1-trifluoroacetone 

Relevant articles and documents

Drug Discovery against Psoriasis: Identification of a New Potent FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor, 1-(4-((1H-Pyrazolo[3,4-d]pyrimidin-4-yl)oxy)-3-fluorophenyl)-3-(5-(tert-butyl)isoxazol-3-yl)urea, That Showed Potent Activity in a Psoriatic Animal Model

Psoriasis is a chronic T-cell-mediated autoimmune disease, and FMS-like tyrosine kinase 3 (FLT3) has been considered as a potential molecular target for the treatment of psoriasis. In this investigation, structural optimization was performed on a lead compound, 1-(4-(1H-pyrazolo[3,4-d]pyrimidin-4-yloxy)phenyl)-3-(4-chloro-3-(trifluoromethyl)phenyl)urea (1), which showed a moderate inhibitory activity againt FLT3. A series of pyrazolo[3,4-d]pyrimidine derivatives were synthesized, and structure-activity relationship analysis led to the discovery of a number of potent FLT3 inhibitors. One of the most active compounds, 1-(4-(1H-pyrazolo[3,4-d]pyrimidin-4-yloxy)-3-fluorophenyl)-3-(5-tert-butylisoxazol-3-yl)urea (18b), was then chosen for in-depth antipsoriasis studies because this compound displayed the highest potency in a preliminary antipsoriasis test. Compound 18b exhibited significant antipsoriatic effects in the K14-VEGF transgenic mouse model of psoriasis, and no recurrence was found 15 days later after the last administration. Detailed mechanisms of action of compound 18b were also investigated. Collectively, compound 18b could be a potential drug candidate for psoriasis treatment.